Glenmark’s drug to treat nausea, psychosis gets FDA nod
India's Glenmark Pharmaceuticals has got the final approval by the USFDA for its generic prochlorperazine maleate tablets, the generic version of compazine of.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
India's Glenmark Pharmaceuticals has got the final approval by the USFDA for its generic prochlorperazine maleate tablets, the generic version of compazine of.
The FDA’s advisory panel recommended full approval of Pfizer’s Covid antiviral treatment Paxlovid for high-risk adults.
The WHO slammed the Chinese authorities for not being transparent in sharing data related to COVID-19 origins and urged Beijing to conduct "investigations.
Jubilant HollisterStier, a subsidiary of India's Jubilant Pharmova, has got Canada's nod for a partially repayable loan of CAD 23.8 million ($17.7 million).
Sanofi, a French pharmaceutical major, announced it would slash the price of insulin, Lantus, by 78% for all U.S. patients with commercial insurance.
Glenmark Specialty SA, a subsidiary of India’s Glenmark Pharmaceuticals, has got investigational new drug clearance from the FDA to conduct clinical trials in.
Mediar Therapeutics gets $105 million financing from Novartis, Pfizer, Eli Lilly and Bristol Myers to advance portfolio of first-in-class fibrosis therapies.
he WHO has identified 55 nations vulnerable to a shortfall in health workers needed to fulfil the UN’s charter for universal health coverage.
The FDA cleared the emergency use of bivalent Pfizer-Biotech COVID-19 vaccine for a single dose booster in children aged six months to four.
Sanofi acquires Provention Bio, and its TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D).